Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : LIfT Biosciences
Deal Size : Undisclosed
Deal Type : Partnership
LIfT BioSciences and Minaris Regenerative Medicine Enter into a Manufacturing Partnership
Details : The partnership is for the development and manufacturing of N-LIfT, LIfT’s first-in-class neutrophil progenitor based Leukocyte Infusion Therapy for the treatment of various cancer indications, including Pancreatic Cancer, Lung Cancer and other solid t...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 16, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : LIfT Biosciences
Deal Size : Undisclosed
Deal Type : Partnership
Details : DCP-001 is currently being evaluated in the ADVANCE II Phase 2 clinical trial to prevent cases of tumor recurrence in Acute Myeloid Leukemia (AML) and in the ALISON Phase 1 clinical trial in ovarian cancer.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
October 17, 2022
Details : Minaris will be responsible for the GMP manufacturing, freezing and shipping of the MVX-ONCO-2 capsules, which will be delivered to clinical sites. The autologous patients’ tumor cells will be processed at the clinical sites.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
February 22, 2021
Reset All
